Jake Van Naarden
CEO of Loxo Oncology at Lilly and President of Lilly Oncology
CEO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | ELI LILLY & Co (LLY) | Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development | $920,192 | $7,586,097 |
| 2024 | ELI LILLY & Co (LLY) | Executive Vice President and President, Loxo@Lilly | $890,385 | $5,773,948 |
| 2023 | ELI LILLY & Co (LLY) | Executive Vice President and President, Loxo@Lilly | $830,769 | $4,886,520 |
| 2022 | ELI LILLY & Co (LLY) | Executive Vice President and President, Loxo@Lilly | $735,577 | $3,621,832 |
| 2021 | ELI LILLY & Co (LLY) | Executive Vice President and President, Loxo@Lilly | $745,649 | $6,122,742 |
Earnings-call appearances
-
ELI LILLY & Co Q3 FY2024 Earnings Call2024-10-30
ELI LILLY & Co (LLY)
-
ELI LILLY & Co Q3 FY2022 Earnings Call2022-12-13
ELI LILLY & Co (LLY)
-
ELI LILLY & Co Q2 FY2022 Earnings Call2022-08-04
ELI LILLY & Co (LLY)
-
ELI LILLY & Co Q1 FY2022 Earnings Call2022-04-14
ELI LILLY & Co (LLY)
-
ELI LILLY & Co Q4 FY2021 Earnings Call2022-02-03
ELI LILLY & Co (LLY)